metformin has been researched along with Lentiginosis, Perioral in 2 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carling, D | 1 |
| Foretz, M | 1 |
| Guigas, B | 1 |
| Viollet, B | 1 |
1 review available for metformin and Lentiginosis, Perioral
| Article | Year |
|---|---|
LKB1: a sweet side to Peutz-Jeghers syndrome?
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Gluconeogenesis; Human | 2006 |
1 other study available for metformin and Lentiginosis, Perioral
| Article | Year |
|---|---|
[From cancer to diabetes treatment : the tumor suppressor LKB1 as a new pharmacological target].
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Cyclic AMP Response El | 2006 |